KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $51.2 million.

  • Pacira BioSciences' Share-based Compensation rose 5.65% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.3 million, marking a year-over-year increase of 9.63%. This contributed to the annual value of $51.2 million for FY2024, which is 6.84% up from last year.
  • As of FY2024, Pacira BioSciences' Share-based Compensation stood at $51.2 million, which was up 6.84% from $47.9 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Share-based Compensation registered a high of $51.2 million during FY2024, and its lowest value of $39.9 million during FY2020.
  • In the last 3 years, Pacira BioSciences' Share-based Compensation had a median value of $48.1 million in 2022 and averaged $49.1 million.
  • Per our database at Business Quant, Pacira BioSciences' Share-based Compensation increased by 18.63% in 2020 and then decreased by 0.41% in 2023.
  • Yearly analysis of 5 years shows Pacira BioSciences' Share-based Compensation stood at $39.9 million in 2020, then increased by 5.83% to $42.2 million in 2021, then rose by 13.84% to $48.1 million in 2022, then dropped by 0.41% to $47.9 million in 2023, then climbed by 6.84% to $51.2 million in 2024.